Consistent with the in vitro results, the proportion of mature DCs (CD11C+CD40+, CD80+, or CD86+) in tumor tissues and tumor-draining lymph nodes (TDLNs) was highly upregulated compared to that in the control group (Figure 3I, 3J, and Figure S3B-E). This evidence concerns the gene CD86 and neoplasm.